Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 99

1.

PARP inhibitors in ovarian cancer.

Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M.

Cancer Treat Rev. 2018 Dec 4;73:1-9. doi: 10.1016/j.ctrv.2018.12.002. [Epub ahead of print] Review.

PMID:
30543930
2.

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.

Faraoni I, Graziani G.

Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487. Review.

3.

How safe is rucaparib in ovarian cancer?

Cosgrove CM, O'Malley DM.

Expert Opin Drug Saf. 2018 Nov 19. doi: 10.1080/14740338.2018.1550067. [Epub ahead of print]

PMID:
30449210
4.

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R.

Int J Mol Sci. 2018 Oct 19;19(10). pii: E3249. doi: 10.3390/ijms19103249. Review.

5.

PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.

Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.

J Geriatr Oncol. 2018 Oct 14. pii: S1879-4068(18)30314-X. doi: 10.1016/j.jgo.2018.10.008. [Epub ahead of print] Review.

PMID:
30333088
6.

The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3. Review.

PMID:
30293710
7.
8.

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA.

Clin Cancer Res. 2018 Dec 15;24(24):6459-6470. doi: 10.1158/1078-0432.CCR-17-1118. Epub 2018 Aug 14.

PMID:
30108102
9.

Using PARP Inhibitors in Advanced Ovarian Cancer.

O'Cearbhaill RE.

Oncology (Williston Park). 2018 Jul 15;32(7):339-43.

10.

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.

Sulai NH, Tan AR.

Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501. Review.

PMID:
30067621
11.

Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.

Arora E, Masab M, Jindal V, Riaz I, Gupta S, Varadi G.

Cureus. 2018 May 24;10(5):e2685. doi: 10.7759/cureus.2685. Review.

12.

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Dal Molin GZ, Omatsu K, Sood AK, Coleman RL.

Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483. doi: 10.1177/1758835918778483. eCollection 2018. Review.

13.

The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.

Chen Y, Du H.

Biomed Pharmacother. 2018 Mar;99:552-560. doi: 10.1016/j.biopha.2018.01.094. Epub 2018 Feb 20. Review.

PMID:
29895102
14.

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.

Domchek SM.

Clin Adv Hematol Oncol. 2018 May;16(5):330-332. No abstract available.

PMID:
29851928
15.

Rucaparib: a new treatment option for ovarian cancer.

Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Lorusso D.

Expert Opin Pharmacother. 2018 May;19(7):765-771. doi: 10.1080/14656566.2018.1464557. Epub 2018 Apr 19.

PMID:
29672168
16.

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.

Colombo I, Lheureux S, Oza AM.

Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018. Review.

17.

Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.

Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P.

Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23. Review.

PMID:
29605737
18.

Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.

Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti M, Nolan RL, Lockman PR.

Pharmacol Res. 2018 Jun;132:47-68. doi: 10.1016/j.phrs.2018.03.021. Epub 2018 Mar 28. Review.

PMID:
29604436
19.

PARP inhibitors for homologous recombination-deficient prostate cancer.

Christenson ES, Antonarakis ES.

Expert Opin Emerg Drugs. 2018 Jun;23(2):123-133. doi: 10.1080/14728214.2018.1459563. Epub 2018 Apr 4. Review.

20.

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.

Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.

PMID:
29567272

Supplemental Content

Loading ...
Support Center